55745-89-6

Basic information

• Product Name: 1-(6-METHYLPYRID-2-YL)PIPERAZINE
• Synonyms: 1-(6-Methylpyridin-2-yl)]piperazine97%;AKOS BBS-00004576;1-(6-METHYL-2-PYRIDYL)PIPERAZINE;1-(6-METHYLPYRID-2-YL)PIPERAZINE;1-(6-METHYLPYRIDIN-2-YL)PIPERAZINE;1-[2-(6-METHYLPYRIDYL)]-PIPERAZINE;Methylpyridylpiperazine;Piperazine, 1-(6-methyl-2-pyridinyl)- (9CI)
• CAS NO: 55745-89-6
• Molecular Formula: C₁₀H₁₅N₃
• Molecular Weight: 177.25
• Product Categories: PIPERIDINE;pharmacetical
• Mol File: 55745-89-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 112-114°C 0,1mm
• Flash Point: 156.5 °C
• Appearance: /
• Density: 1.059g/cm³
• Vapor Pressure: 0.000122mmHg at 25°C
• Refractive Index: 1.543
• PKA: 9.14±0.19(Predicted)
• CAS DataBase Reference: 1-(6-METHYLPYRID-2-YL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-METHYLPYRID-2-YL)PIPERAZINE(55745-89-6)
• EPA Substance Registry System: 1-(6-METHYLPYRID-2-YL)PIPERAZINE(55745-89-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 55745-89-6(Hazardous Substances Data)

Usage

Uses

1-(6-Methylpyridin-2-yl)piperazine is a compound used in the preparation of anticonvulsant agents.

InChI:InChI=1/C10H15N3/c1-9-3-2-4-10(12-9)13-7-5-11-6-8-13/h2-4,11H,5-8H2,1H3

Upstream product

• 110-85-0 piperazine 
• 18368-63-3 6-chloro-2-picoline 
• 5315-25-3 2-bromo-6-methylpyridine 

Downstream Products

• 1400654-87-6 C₂₇H₃₅N₅O₄ 
• 1373046-65-1 N-(1-(4-cyanophenyl)-3,3-dimethyl-1-oxobutan-2-yl)-4-(6-methylpyridin-2-yl)piperazine-1-carboxamide 
• 1373046-67-3 N-(1-(4-cyanophenyl)-3,3-dimethyl-1-oxobutan-2-yl)-4-(6-methylpyridin-2-yl)piperazine-1-carboxamide 
• 1373046-68-4 N-(1-(4-cyanophenyl)-3,3-dimethyl-1-oxobutan-2-yl)-4-(6-methylpyridin-2-yl)piperazine-1-carboxamide 

Relevant articles and documents

Heteroaromatic acetamide derivative, preparation and applications thereof

The present invention provides a heteroaromatic acetamide derivative, a preparation and applications thereof, wherein the derivative comprises a pharmaceutically acceptable salt and/or a solvate thereof. According to the present invention, the experiment results prove that the heteroaromatic acetamide derivative can specifically bind to transient receptor potential ankyrin 1 (TRPA1) and inhibit orreduce the activity of TRPA1, and can be used for treating diseases mediated by TRPA1; and the inhibitor of the present invention further comprises a pharmaceutical composition of the compound, and amethods for preparing the compounds. The derivative has a general formula defined in the specification.

N?-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling

Transglutaminase 2 (TGase 2)-catalyzed transamidation represents an important post-translational mechanism for protein modification with implications in physiological and pathophysiological conditions, including fibrotic and neoplastic processes. Consequently, this enzyme is considered a promising target for the diagnosis of and therapy for these diseases. In this study, we report on the synthesis and kinetic characterization of N?-acryloyllysine piperazides as irreversible inhibitors of TGase 2. Systematic structural modifications on 54 new compounds were performed with a major focus on fluorine-bearing substituents due to the potential of such compounds to serve as radiotracer candidates for positron emission tomography. The determined inhibitory activities ranged from 100 to 10?000 M-1 s-1, which resulted in comprehensive structure-activity relationships. Structure-activity correlations using various substituent parameters accompanied by covalent docking studies provide an advanced understanding of the molecular recognition for this inhibitor class within the active site of TGase 2. Selectivity profiling of selected compounds for other transglutaminases demonstrated an excellent selectivity toward transglutaminase 2. Furthermore, an initial pharmacokinetic profiling of selected inhibitors was performed, including the assessment of potential membrane permeability and liver microsomal stability.